EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of December 19, 2016 (the “Separation Date”), Ryan Brenneman ceased serving as the Chief Financial Officer and principal financial and accounting officer of EyeGate Pharmaceuticals, Inc. (the “Company”). Mr. Brenneman’s departure from the Company did not result from any disagreement regarding the Company’s financial reporting or accounting policies, procedures, estimates or judgments. In connection with Mr. Brenneman’s departure, Stephen From, the Company’s President and Chief Executive Officer, assumed the role of principal financial and accounting officer effective as of the Separation Date.

About EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG)

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Recent Trading Information

EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) closed its last trading session up +0.03 at 1.78 with 107,512 shares trading hands.